IDYA · IDEAYA Biosciences
AI read · Good for IDYA
The AI's read
The higher target reflects Wedbush's favorable view of IDEAYA's clinical progress and finances. It is an analyst opinion, not a new trial result or a change announced by the company.
Wedbush raised its price target for IDEAYA Biosciences to $63, up from $60.
Good for IDYA
Wedbush kept its Outperform rating and raised its IDEAYA target, citing its review of clinical progress and finances. This is a favorable analyst view, not a new trial result or company forecast.
Get alerts for IDYA
Follow IDEAYA Biosciences (IDYA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IDYAFree on the App Store and Google Play, or on the web.